Value of pharmacologic stress echocardiography in risk stratification of patients with single-vessel disease: a report from the echo-persantine and echo-dobutamine international cooperative studies
Lauro Cortigiani, MDa,b,
Eugenio Picano, MD, PhDa,b,
Patrizia Landi, BSca,b,
Mario Previtali, MDa,b,
Salvatore Pirelli, MDa,b,
Paolo Bellotti, MDa,b,
Riccardo Bigi, MDa,b,
Ornella Magaia, MDa,b,
Alfonso Galati, MDa,b,
Eugenio Nannini, MDa,b on Behalf of the Echo-Persantine (EPIC) and Echo-Dobutamine International Cooperative (EDIC) Study Groups
a Consiglio Nazionalle delle Ricerche (CNR) Institute of Clinical Physiology, Pisa, Italy
b Unità Operativo Malattie Cardiovascolari, Ospedale Campo di Marte, Lucca, Italy
View larger version (14K):
[in a new window]
|
Figure 1 Cumulative survival rates free of hard cardiac events (death and nonfatal infarction) in 494 medically treated patients with negative (Neg) or positive (Pos) stress testing results.
|
|
View larger version (12K):
[in a new window]
|
Figure 2 Cumulative survival rates free of hard cardiac events (death and nonfatal infarction) in 260 invasively treated patients with negative (Neg) or positive (Pos) stress testing results before coronary revascularization.
|
|
|
